Skyrizi

This page shows the latest Skyrizi news and features for those working in and with pharma, biotech and healthcare.

Novartis eyes potential new indication for Cosentyx

This includes Johnson &Johnson’s Tremfya (guselkumab), AbbVie’s Skyrizi (risankizumab), Eli Lilly’s Taltz (ixekizumab) and Pfizer’s Xeljanz (tofacitinib citrate).

Latest news

J&J's Tremfya filed for approval in US for psoriatic arthritis

This includes Novartis’ Consentyx (secukinumab), AbbVie’s Skyrizi (risankizumab), Eli Lilly’s Taltz (ixekizumab) and Pfizer’s Xeljanz (tofacitinib citrate) , which are all already approved in psoriatic arthritis.
FDA clears Lilly’s Taltz for ankylosing spondylitis

Meanwhile, the new approval also keeps Taltz ahead of some other new competitors, particularly AbbVie/Boehringer Ingelheim’s new IL-23 inhibitor Skyrizi (risankizumab) which AbbVie thinks can become a $5bn ... Skyrizi has been approved for psoriasis so
NICE’s fast-track catapults Skyrizi into market

This means the NHS across England has a month from today to make preparations for prescribing of Skyrizi to begin. ... The NICE approval means Skyrizi is recommended for severe psoriasis treatment in adults who have failed conventional systemic therapies.
AbbVie scores FDA approval for arthritis treatment upadacitinib

AbbVie has been betting on its new products upadacitinib for RA and Skyrizi for psoriasis to combat Humira’s decline.
AbbVie’s Skyrizi gets rapid ‘yes’ from NICE

The positive Final Appraisal Document (FAD) means Skyrizi (risankizumab) is recommended for severe psoriasis treatment in adults who have failed conventional systemic therapies. ... The recommendation means that the NHS in England will make Skyrizi

More from news
Approximately 5 fully matching, plus 11 partially matching documents found.

Latest Intelligence

Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

Developed by Boehringer Ingelheim and AbbVie, Skyrizi is a monoclonal antibody that inhibits the pro-inflammatory cytokine IL-23. ... Forecast sales for Skyrizi in 2023 are $1.74bn. AR-101 from Aimmune Therapeutics addresses peanut allergy.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Medical Writer – Medical Communications – North West – In...: Excellent Remuneration Package

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Account Director, Medical Education: Salary TBC

Senior / Principal Medical Writers wanted - MedComms - Various U...: Excellent Remuneration Packages

Experienced / Senior Medical Writer - Excellent Progression Oppo...: Excellent Salary and Benefits on offer

Senior Medical Writer: Salary TBC

Editorial Assistants - Medical Communications agency - Cheshire: Excellent Remuneration Package

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Senior Copywriter: Salary TBC

Senior Account Manager / Account Director - MedComms - London: Highly competitive salary &package

Subscribe to our email news alerts

PMHub

Add my company

Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe: By Richard Springham...
The Golden Goose: Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?: Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...